多发性硬化和红斑狼疮等自身免疫性疾病只不过是对不断变化的食物摄入的反复炎症反应，被随意归入各种疾病名称；红斑狼疮可以通过遵循 Tayebat 体系来治疗。
原始表述
الام اس التصلب اللوايحي ده سببه ايه او مثلا الذئبه الحمراء سببها ايه يا حبيبي اخوك انت كلها اعراض التهابيه متكرره في جسمك واحنا قسمناها بقى عملناها كاتيجوري حسب العرض اللي بيجي لك | علاج الذئبه الحمراء يمشي على النظام يمشي على النظام بس
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
多发性硬化和红斑狼疮等自身免疫性疾病只不过是对不断变化的食物摄入的反复炎症反应，被随意归入各种疾病名称；红斑狼疮可以通过遵循 Tayebat 体系来治疗。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًاFAQs (打开来源)
- 发布日期
- 2026年4月6日
- 时间戳
- 无（转录文本不含时间信息）
- 归属的不确定性
- Machine-generated or CC transcript of a live stream; wording may contain transcription errors; context is conversational. original_ar joins separate verbatim passages with ' | '.
- 所声称的机制
Variable dietary inputs trigger varying inflammatory reactions; diet removes the cause.
- 所声称的健康影响
Treatment of MS, lupus and other autoimmune diseases by diet.
- 涉及人群
People with autoimmune diseases.
- Elawady 设定的地域限制
none found
来源版本存在差异
علاج الذئبه الحمراء يمشي على النظام يمشي على النظام بس
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live! الأكل وراء كل مشاكلك (打开来源)
- 发布日期
- 2025年7月20日
- 时间戳
- 1:15:07 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
科学评估
错误 – 该说法与可靠证据相矛盾。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
Autoimmune diseases are food reactions; the diet treats lupus.
2. 哪些内容可证实是正确的？
Diet can matter in some immune-mediated diseases (e.g. coeliac disease is triggered by gluten), and inflammation is a shared feature of many diseases.
3. 哪些内容是错误或夸大的？
MS and lupus are distinct diseases with specific autoantibodies, imaging and organ involvement, not arbitrary labels. There is no evidence that diet alone controls them; guideline treatment (hydroxychloroquine, immunosuppressants, biologics in SLE; disease-modifying therapy in MS) prevents organ damage and relapses.
4. 哪些内容仍不明确？
Whether specific dietary patterns modestly help symptoms, fatigue or inflammation markers as add-ons: a 2026 meta-analysis found some diets may lower CRP in MS (low certainty; no effect on relapses shown) (I-AUTO-104).
5. 哪些研究支持该说法？
None.
6. 哪些研究与该说法相矛盾？
EULAR SLE 2023 (I-GUT-10); Cochrane MS diet 2020 (I-GUT-09); randomised withdrawal trial: stopping hydroxychloroquine in stable lupus led to flares in 16/22 vs 9/25 (RR 2.5) (I-AUTO-101); Cochrane network meta-analysis 2024: MS drugs reduce relapses by about 40-47% over 24 months (I-AUTO-102); ECTRIMS/EAN MS drug guideline (I-AUTO-103).
7. 对德国和欧洲而言情况如何？
Treatment standards in Germany/Europe follow EULAR and European MS guidelines.
8. 关于埃及的已知情况是什么？
Not region-specific.
9. 合理的实际结论是什么？
健康饮食可以作为补充，但绝不能取代自身免疫性疾病的专科治疗。
评估详情
- 证据确定性的依据
SLE and MS are defined by specific immunological and pathological features and are managed with disease-modifying drugs that prevent organ damage (EULAR 2023 SLE recommendations). A Cochrane review of 30 dietary trials in MS found insufficient evidence that dietary interventions change relapses or disability. No trial of the Tayebat diet in any autoimmune disease exists.
- 来源质量
Video statements; no evidence offered.
- 地区可推广性
Not region-specific.
- 个体例外情况
Coeliac disease is a recognised autoimmune disease with a dietary trigger (gluten); this is an exception, not the rule.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
已被科学证据否定 – 高质量证据显示情况恰恰相反，或该说法与已确立的生理学知识相矛盾。
研究问题: In people with systemic lupus erythematosus or multiple sclerosis, are these diseases merely food-triggered inflammation, and can following a diet (the Tayebat system) replace immunosuppressive or disease-modifying drug treatment?
研究问题详解 (PICO)
- 人群
- People with SLE or MS
- 干预或暴露
- Diet-only management (Tayebat system) / dietary interventions
- 对照
- Guideline drug treatment (hydroxychloroquine, immunosuppressants, biologics; MS disease-modifying therapies)
- 地域范围
- universal biology
- 结局指标
- Flares/relapses
- Organ damage, disability progression
- Inflammatory markers
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Diet and inflammation markers in MS
Pingel WR et al.. Mult Scler Relat Disord 2026 · PMID 41422672 · DOI 10.1016/j.msard.2025.106913 Meta分析已核查摘要新增Some diets (Mediterranean, plant-based, calorie-restricted) may lower CRP in people with MS.
- 实际结果
- CRP reduced in 5 of 7 RCTs; leptin/adiponectin unchanged; NutriGRADE low.
- 方法学质量
- low (13 small RCTs; surrogate markers; COI of one author)
- 相关性
- indirect: diet can modulate inflammation markers, not disease course
- 局限
- No relapse or disability outcomes.
哪些证据不支持该说法？
Drugs for relapsing multiple sclerosis
Gonzalez-Lorenzo M et al.. Cochrane Database Syst Rev 2024 · PMID 38174776 · DOI 10.1002/14651858.CD011381.pub3 Meta分析已核查摘要新增Disease-modifying drugs strongly reduce MS relapses.
- 实际结果
- Relapses at 24 months: cladribine RR 0.53 (0.44-0.64), alemtuzumab 0.57 (0.47-0.68), natalizumab 0.56 (0.48-0.65), high certainty.
- 方法学质量
- high (Cochrane NMA, 50 RCTs, 36,541 participants)
- 相关性
- direct for drug efficacy; indirect for diet
- 局限
- Most trials industry-sponsored; little evidence beyond 2 years.
Stopping hydroxychloroquine in lupus
Canadian Hydroxychloroquine Study Group. N Engl J Med 1991 · PMID 1984192 · DOI 10.1056/NEJM199101173240303 随机对照试验已核查摘要新增Stopping hydroxychloroquine in stable lupus causes flares.
- 实际结果
- Flares 16/22 (placebo) vs 9/25 (HCQ); RR 2.5 (1.08-5.58).
- 方法学质量
- high (double-blind RCT) but small
- 相关性
- direct: consequence of withdrawing standard therapy
- 局限
- 47 patients, 24 weeks.
EULAR 2023 lupus treatment
Fanouriakis A et al.. Ann Rheum Dis 2024 · PMID 37827694 · DOI 10.1136/ard-2023-224762 指南 / 立场声明全文，含结构化偏倚风险评估EULAR 2023: HCQ for all SLE patients, not to be stopped without unacceptable adverse effects; diet only as a non-pharmacological adjunct.
- 实际结果
- 13 recommendations; HCQ discontinuation linked to flares.
- 方法学质量
- high (EULAR guideline, SLR-based)
- 相关性
- direct
- 局限
- Guideline, not primary data.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
SLE and MS are distinct immune-mediated diseases with specific autoantibodies, imaging and pathology; drug treatment prevents flares, relapses and organ damage. Diet may modestly influence inflammation markers but has not been shown to control either disease.
为什么有些研究权重更大
Randomised drug trials and the Cochrane NMA (high certainty) outweigh small surrogate-marker diet trials (low certainty). No study of the Tayebat diet exists.
因果关系是否已确立？ 是，已确立 Causal efficacy of DMTs and of continuing HCQ is established by RCTs; the claimed causal role of 'changing food inputs' as the cause of MS/SLE is not supported.
仍存在的不确定性
Whether specific dietary patterns modestly reduce fatigue or inflammation as add-ons.
合理的结论
Diet cannot replace treatment of lupus or MS; claiming so endangers patients.
为什么研究结果看起来互相矛盾？
No real conflict: diet trials measure surrogate inflammation markers or fatigue as add-ons to drug treatment, whereas the claim concerns replacing treatment; the questions differ.
这是否取决于国家？
- 一般生物学效应
- Universal immunology and pharmacology.
- 饮食习惯
- Not habit-dependent.
- 食品原产地
- Not applicable.
- 污染物
- Not applicable.
- 本国生产条件
- Not applicable.
- 法律规则
- Not applicable.
- 实际监测数据
- No Egyptian data on outcomes of diet-only management were found.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Crude RR from counts and CI log-symmetry – Crude RR 2.02 (72.7% vs 36.0%; risk difference 36.7 points, NNH about 3); reported RR 2.5 with log-symmetric CI (geometric midpoint 2.46); severe exacerbation RR 6.1 imprecise (CI includes 1). 已重新计算
- CI log-symmetry of NMA RRs – All checked RRs centred on their CIs; absolute effects not computable without placebo rates. 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Relapse/flare control with diet-only management vs guideline drug therapy
- 起始等级
- 高（随机试验）
- 降级理由
- indirectness (no trial of diet replacing drugs; evidence comes from drug-vs-placebo and withdrawal trials)
- 升级理由
- large effect of DMTs (RR about 0.5)
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- EULAR: EULAR recommendations for the management of SLE: 2023 update (2024) · 原始文献
HCQ recommended for all patients and not to be discontinued without unacceptable adverse effects; non-pharmacological measures (healthy balanced diet) as adjuncts. - ECTRIMS/EAN: Guideline on the pharmacological treatment of people with MS (2018) · 原始文献
GRADE-based recommendations for EMA-approved disease-modifying drugs (abstract read).
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | TITLE:(fasting) AND (autoimmune OR "rheumatoid arthritis" OR "multiple sclerosis" OR lupus) AND ("systematic review" OR "meta-analysis") | 支持性证据 | 164 | |
| Europe PMC | 2026年10月26日 | (diet OR dietary OR nutrition) AND ("systemic lupus erythematosus") AND ("systematic review" OR "meta-analysis") AND (randomized OR randomised OR trials) | 支持性证据 | 4390 | |
| Europe PMC | 2026年10月26日 | TITLE:"dietary interventions" AND TITLE:"lupus" | 支持性证据 | 0 | |
| Europe PMC | 2026年10月26日 | (fasting OR "fasting-mimicking" OR "calorie restriction" OR "ketogenic") AND ("multiple sclerosis") AND (randomized OR randomised) AND (pilot OR trial) | 支持性证据 | 3554 | |
| Europe PMC | 2026年10月26日 | TITLE:"multiple sclerosis" AND TITLE:("Mendelian randomization" OR "mendelian randomisation") AND (obesity OR "body mass index" OR BMI) | 支持性证据 | 49 | |
| Europe PMC | 2026年10月26日 | (diet OR dietary) AND ("multiple sclerosis") AND ("risk" ) AND ("umbrella review" OR "systematic review and meta-analysis") AND TITLE:(diet OR dietary) | 支持性证据 | 98 | |
| Europe PMC | 2026年10月26日 | TITLE:"hydroxychloroquine" AND (withdrawal OR discontinuation) AND lupus AND (randomized OR randomised) | 反对性证据 | 182 | |
| Europe PMC | 2026年10月26日 | TITLE:"withdrawing hydroxychloroquine" | 反对性证据 | 1 | |
| Europe PMC | 2026年10月26日 | JOURNAL:"Cochrane Database Syst Rev" AND TITLE:"relapsing-remitting multiple sclerosis" AND (immunomodulators OR "network meta-analysis") | 反对性证据 | 4 | |
| PubMed | 2026年10月26日 | ECTRIMS/EAN guideline record fetched by PMID 29353550 (efetch) | 指南 | 1 | |
| PubMed | 2026年10月26日 | (diet[ti] OR dietary[ti] OR fasting[ti]) AND (lupus[ti] OR "multiple sclerosis"[ti]) AND (randomized controlled trial[pt] OR meta-analysis[pt]) | 支持性证据 | 51 | |
| PubMed | 2026年10月26日 | ("diet therapy"[MeSH] OR fasting[MeSH]) AND "Lupus Erythematosus, Systemic"[MeSH] AND (remission OR "disease activity") | 支持性证据 | 14 | |
| PubMed | 2026年10月26日 | (hydroxychloroquine[ti] OR immunosuppressive[ti]) AND lupus[ti] AND (withdrawal[ti] OR discontinuation[ti] OR tapering[ti]) | 反对性证据 | 19 | |
| PubMed | 2026年10月26日 | "multiple sclerosis"[ti] AND (disease-modifying[ti] OR immunomodulators[ti]) AND (network meta-analysis[pt] OR "Cochrane Database Syst Rev"[ta]) | 反对性证据 | 23 |
待解决的问题
Number of patients following the system who stopped immunosuppression; no data found.
核查深度如何？
6 项相关研究：1 项核查了全文（其中 1 项进行了结构化偏倚风险评估），5 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 错误 (中)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 错误 (中)
New RCT evidence (HCQ withdrawal; Cochrane DMT NMA) strengthens the contradiction but the claim's 'diet replaces drugs' part has never been tested directly, so certainty stays moderate (indirectness).
新来源: I-AUTO-101 I-AUTO-102 I-AUTO-103 I-AUTO-104
通俗解释
多发性硬化和红斑狼疮是真实的、特定的疾病，在这些疾病中免疫系统会攻击身体。现代药物可以预防肾脏、大脑和其他器官受损。关于多发性硬化饮食的研究并未表明单靠饮食就能控制这种疾病。只用饮食治疗红斑狼疮没有任何研究支持。
与该说法相关的研究
支持该说法的研究 (0)
该组中没有研究。
与该说法相矛盾或限制该说法的研究 (5)
-
EULAR 2023 lupus treatment
Fanouriakis A et al.. Ann Rheum Dis 2024 · PMID 37827694 · DOI 10.1136/ard-2023-224762指南 / 立场声明独立交叉核查全文，含结构化偏倚风险评估Hydroxychloroquine for all patients; immunosuppressants and biologics to control disease.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
-
Diet and multiple sclerosis (Cochrane)
Parks NE et al.. Cochrane Database Syst Rev 2020 · PMID 32428983 · DOI 10.1002/14651858.CD004192.pub4系统综述独立交叉核查已核查摘要No reliable evidence that diet changes relapses or disability in MS.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
-
Stopping hydroxychloroquine in lupus
Canadian Hydroxychloroquine Study Group. N Engl J Med 1991 · PMID 1984192 · DOI 10.1056/NEJM199101173240303随机对照试验独立交叉核查已核查摘要★ 关键研究In stable lupus, people switched to placebo had far more flares (73%) than those who kept taking hydroxychloroquine (36%).
Stopping HCQ in stable lupus doubled-to-tripled flares (16/22 vs 9/25).
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test whether HCQ can be stopped in stable lupus.
- 研究是如何开展的？
Double-blind RCT, 24 weeks.
- 研究了多少人、动物或样本？
47 Canadian patients with stable SLE.
- 实际发现了什么？
More and earlier flares after withdrawal.
- 观察到的效应有多大？
RR 2.5 (1.08-5.58).
- 研究结果对日常生活意味着什么？
Stopping lupus medicine leads to flares; diet should not replace it.
- 该研究有哪些局限？
Small, short.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'lupus is treated by following the system' as a replacement for medicine.
- 研究结果是否适用于德国和欧洲？
Applies; same physiology.
- 从该研究中明确不能得出什么结论？
Effects of adding a diet to HCQ.
-
Drugs for relapsing multiple sclerosis
Gonzalez-Lorenzo M et al.. Cochrane Database Syst Rev 2024 · PMID 38174776 · DOI 10.1002/14651858.CD011381.pub3Meta分析独立交叉核查已核查摘要★ 关键研究Several MS drugs cut relapses roughly in half over two years compared with placebo.
DMTs reduce MS relapses by about 40-47% over 24 months (high certainty for several drugs).
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare MS drugs.
- 研究是如何开展的？
Cochrane network meta-analysis.
- 研究了多少人、动物或样本？
50 trials, 36,541 people.
- 实际发现了什么？
Large relapse reductions with several DMTs.
- 观察到的效应有多大？
RR about 0.53-0.57 at 24 months.
- 研究结果对日常生活意味着什么？
MS treatment works; it should not be replaced by diet.
- 该研究有哪些局限？
Industry trials; short follow-up.
- 它对 Elawady 的具体说法说明了什么？
Contradicts diet as replacement therapy.
- 研究结果是否适用于德国和欧洲？
Applies; same physiology.
- 从该研究中明确不能得出什么结论？
Long-term disability beyond 2-3 years.
-
European MS treatment guideline
Montalban X et al.. Mult Scler 2018 · PMID 29353550 · DOI 10.1177/1352458517751049指南 / 立场声明独立交叉核查已核查摘要★ 关键研究European neurology societies recommend disease-modifying drugs for MS.
European MS standard of care is pharmacological disease-modifying treatment.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Guide MS drug treatment.
- 研究是如何开展的？
GRADE guideline.
- 研究了多少人、动物或样本？
not applicable
- 实际发现了什么？
21 recommendations on DMDs.
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
MS is treated with specific drugs.
- 该研究有哪些局限？
Not the newest edition.
- 它对 Elawady 的具体说法说明了什么？
Contradicts diet as MS treatment.
- 研究结果是否适用于德国和欧洲？
European standard.
- 从该研究中明确不能得出什么结论？
Role of diet as add-on.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (1)
-
Diet and inflammation markers in MS
Pingel WR et al.. Mult Scler Relat Disord 2026 · PMID 41422672 · DOI 10.1016/j.msard.2025.106913Meta分析独立交叉核查已核查摘要★ 关键研究Some diets may lower inflammation markers in MS, but the evidence is weak and does not show effects on relapses or disability.
Some diets may lower CRP in MS (low certainty); no effect on disease outcomes shown.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test diet effects on inflammation in MS.
- 研究是如何开展的？
Meta-analysis of 13 RCTs.
- 研究了多少人、动物或样本？
891 people with MS.
- 实际发现了什么？
CRP reduced in 5 of 7 trials.
- 观察到的效应有多大？
Adipokines not changed.
- 研究结果对日常生活意味着什么？
Healthy eating may be a useful addition to MS care, not a replacement.
- 该研究有哪些局限？
Surrogate outcomes; low certainty.
- 它对 Elawady 的具体说法说明了什么？
Partly supports a role of diet in inflammation; not a cure.
- 研究结果是否适用于德国和欧洲？
Applies; same physiology.
- 从该研究中明确不能得出什么结论？
Effect on relapses or disability.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Treatment standards in Germany/Europe follow EULAR and European MS guidelines.
埃及
Not region-specific.
在我的国家适用什么？
一般科学评估
错误 这一说法是错误的：红斑狼疮和多发性硬化是特定的免疫性疾病，药物治疗可以预防发作和复发，没有研究表明饮食能够替代药物治疗。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.. Fanouriakis A et al.. Ann Rheum Dis 2024 · PMID 37827694 · DOI 10.1136/ard-2023-224762
- Dietary interventions for multiple sclerosis-related outcomes.. Parks NE et al.. Cochrane Database Syst Rev 2020 · PMID 32428983 · DOI 10.1002/14651858.CD004192.pub4
- A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.. Canadian Hydroxychloroquine Study Group. N Engl J Med 1991 · PMID 1984192 · DOI 10.1056/NEJM199101173240303
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.. Gonzalez-Lorenzo M et al.. Cochrane Database Syst Rev 2024 · PMID 38174776 · DOI 10.1002/14651858.CD011381.pub3
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.. Montalban X et al.. Mult Scler 2018 · PMID 29353550 · DOI 10.1177/1352458517751049
- The effect of dietary interventions on peripheral markers of inflammation among people with multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials.. Pingel WR et al.. Mult Scler Relat Disord 2026 · PMID 41422672 · DOI 10.1016/j.msard.2025.106913